Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04712851 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
A Phase 2 study of Cervical Intraepithelial Neoplasia and Cervical Squamous Cell Carcinoma In Situ, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04712851: Recruiting Phase 2 study of Cervical Intraepithelial Neoplasia and Cervical Squamous Cell Carcinoma In Situ, sponsored by Jonsson Comprehensive Cancer Center.
NCT04712851 is a Phase 2 study of Cervical Intraepithelial Neoplasia and Cervical Squamous Cell Carcinoma In Situ that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 25 participants, below the 267-participant average among 6 other Cervical Intraepithelial Neoplasia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04712851, a Phase 2 study of Cervical Intraepithelial Neoplasia and Cervical Squamous Cell Carcinoma In Situ, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
Will assess the percent of patients with pathologic complete response at 6 months.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
Study Locations (1)
California
- University of California at Los Angeles / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
What NCT04712851 shows while recruiting
NCT04712851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 267-participant average among 6 other Cervical Intraepithelial Neoplasia trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Cervical Intraepithelial Neoplasia appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT04712851 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04712851 about?
NCT04712851 is a clinical study titled "Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia". This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT04712851?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-06-30. Estimated completion is 2028-01-31.
What conditions does trial NCT04712851 study?
This clinical trial studies the following conditions: Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2.
What interventions are being tested in trial NCT04712851?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04712851?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04712851 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Intraepithelial Neoplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
COMPLETED · Phase 2
-
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
COMPLETED · Phase 2
-
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
RECRUITING · Phase 1
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings
ACTIVE NOT RECRUITING · NA
-
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI